Skip to main content

Hemab Therapeutics Holdings, Inc Investor Event Transcript, Nov 17, 2026

Hemab Therapeutics Holdings, Inc. (COAG)

Hemab's CEO said the phase 3 Glansman study uses a single-arm design with approximately 75 patients. The company has more than $400 million in cash, with runway well into 2029. AI summary

Investor Event Transcript 2026-11-17 For: 2026-12-31
Added on November 17, 2026

Conference Transcript - COAG 2026-11-17

Benny Sorensen, CEO

All set. Ready? Yes.

Maury Raycroft, Analyst — Jefferies

Okay. Hi, everyone. My name is Maury Raycroft and I'm one of the biotech analysts at Jeffrey's. I'd like to welcome the CEO of Hemab, Benny Sorensen. Thanks so much for joining us today, Benny. Thank you for having us. And we're going to do a fireside chat format. So for those who are new to the story, if you can give a brief intro to Collette.

Benny Sorensen, CEO

Sure. So Hemab Therapeutics is a biotech company where we are pursuing a vision of reimagining treatment of blood coagulation disorders. So it's a biotech company exclusively focused in coagulation, hence the COAG ticker. And we're proud of the progress we have made. We have a molecule, Cytasimac, that is now in phase 3 pivotal trials in Glansman's thrombustenia. The same molecule is being prosecuted in a second indication called Factor 7 deficiency, where we have Phase 2 data coming soon. I'm sure we'll chat about that. And then the second asset, HMBOO2, is a molecule for prophylaxis for Wembleyman's disease. And then our latest, HMBOO3, is for heavy menstrual bleeding.

Maury Raycroft, Analyst — Jefferies

Yep. Yeah, it's a great intro. And maybe let's start off with Cetacimig for Glansman. You just announced the start of your Phase 3 study. We saw the trials posted on CT.gov a couple days ago. FDA recommended considering a randomized controlled study while acknowledging the feasibility challenges in glansmen. Can you provide more color on the feedback and whether any specifics related to how the single-arm study should be run were discussed?

Benny Sorensen, CEO

You know, we've had really, really constructive dialogue with the regulatory authorities here and discussed, you know, what would be the best way to kind of advance pseudasmic as a first-ever prophylactic treatment for glansmen. And I think it's not unusual that regulators would kind of like, have you considered a randomized trial versus a single-arm trial? The dialogue has been very constructive. It's very clear, based on the phase two data we have, that we need to somewhat control a substantial amount of variability. And the strongest way of doing that is a single-arm trial. It will enable us to do 90% power for a minimum 50% effect. And we think that it's super important to kind of minimize the technical risk to really give the largest possible hope for these patients in having a first-ever prophylactic treatment.

Maury Raycroft, Analyst — Jefferies

Yeah, makes sense. And as far as the endpoints go and everything, you're not compromising anything there?

Benny Sorensen, CEO

No, we are fully aligned on the primary endpoint being the annualized treated bleed rates. We have collaborated really closely with the agency building a really state-of-art electronic validated bleed diary. That gives us an opportunity to collect this data with really high quality. So the primary endpoint, all secondary endpoint, fully endorsed with the regulators, our approach to analyzing the data. A long time ago, we agreed on the dose, the dose regime. So there's a lot more that we agree on than we are still discussing.

Maury Raycroft, Analyst — Jefferies

Makes sense. And as you get the phase three started in the U.S., maybe talk about the status. It's XCUS, and it's an ultra-rare disease. How many sites do you need for this study? You're going to have 75 patients.

Benny Sorensen, CEO

Yeah, so it's approximately 75 patients. We've spent, you know, almost a half a year building, you know, a really deep understanding of feasibility. We have identified multiple more patients than the 75 that we need to enroll. You can expect this to be enrolled in multiple countries and, you know, multiple sites, It's more sites than we probably have patients need for, but that's just the best practices when it comes to executing in rare disease. Right now, we are open in the U.S. as well as two non-U.S. regions as well. First half of next year, we'll provide a little bit more metrics on enrollment and, you know, timelines, And so that you guys can start putting a dot on the ground on when the data comes.

Maury Raycroft, Analyst — Jefferies

Okay. Yeah, that's helpful. I think we're estimating you could potentially get the data in, like, second half of 2028. Do you think that's a reasonable time frame?

Benny Sorensen, CEO

You know, I usually kind of, you know... Remind you of the two times three by 2030, so there will be two commercial programs in 2030, sooner is better, two late-stage programs, two early-stage programs. If we are, you know, getting close to that, we have built a really significant multi-product company.

Maury Raycroft, Analyst — Jefferies

Right. Okay. And wondering if FDA gave any specifics on how the results would be reviewed, were there any statistical thresholds defined for efficacy, and what do you need to show to get clear conviction?

Benny Sorensen, CEO

Yeah, by the way, nothing has changed here. We have been aligned for a long time. You know, we want, you know, 90 percent power to show minimum 50 percent reduction. You know that if you know in the intention to treat analysis in our phase two, we got to 50. In the protocol analysis of the low dose weekly regime, we see about 80 percent reduction. We feel really confident that we've designed a registrational trial that certainly has the potential to yield really compelling results.

Maury Raycroft, Analyst — Jefferies

Got it. And if you hit your best or base case efficacy scenarios, how will this translate to market opportunity, and how will you price this drug?

Benny Sorensen, CEO

Yep. By the way, I think that's another part of, you know, we have not tried to reduce variability by developing kind of unrealistic eligibility criteria that eventually could result in a narrow label and thereby generate restrictions. So, you know, the way it's designed is really to kind of embrace as many of the Glansman patients as possible. So if there's 800 to 1,000 patients in the United States, you know, on the other side of this trial, the vast majority of them will be eligible.

Maury Raycroft, Analyst — Jefferies

Got it. Okay. And on pricing, is there anything you're saying on that at this point?

Benny Sorensen, CEO

Nothing has changed. I think we keep on saying if you want a reference point, we think a good reference point is the price tag of Himlibra. You know, the list cost is about $800,000 per patient per year. Adjusted for weight brackets, it's probably averaged around 650, and that's a base case. You know, I think I've heard about 15 times today, you know, but Glouncement is more rare. There may be a higher unmet needs, and yeah, but let's have a look at that. You know, it's much easier to adjust things up than down.

Maury Raycroft, Analyst — Jefferies

Right, yeah, yeah, it makes sense. And for Factor 7, you're going to have an updated data cut at ASH from your Phase 2B. What's going to be new in that update, and what is the magnitude of partial thromboplastin, time shortening, and factor VIIa accumulation you want to see to expand the study to more sites?

Benny Sorensen, CEO

Yeah, by the way, so this is the first ever clinical data of Sotacimac in factor VII deficiency. And I'm super proud of this because it's such a demonstration of the power of translational coagulation biology. What we have said in the abstract is we see up to five-fold increase in a total of seven. We see more than a 50% reduction in the pro-thrombin time. Yeah, I think this is important because we have actually, in a small number of patients, pretty much recapitulated our entire preclinical package, and we have also leveraged our deep understanding of the molecular biology of factor VII deficiency, so based on knowing the mutation, builds a data package that actually can predict whether you are going to be a responder or not a responder. So kind of for the first time in coagulation biology, we can actually use the molecular knowledge to guide whether you're going to benefit or not. I think that's pretty cool.

Maury Raycroft, Analyst — Jefferies

Yeah, yeah, interesting. And for this study, I guess, what are the next steps going to be, and what do you think about the development path there and some of the options?

Benny Sorensen, CEO

Yeah, we kind of – and it's so appropriate to be here in London. We did the first couple of patients, just one site here in the U.K., and the data we've generated are really, in our eyes, binary in a way that this justifies increasing the investment, opening additional countries, additional sites. We obviously need to generate some volume in the data before we can land final dose-dose regime. If we actually let the Glanzman study advance a little in the background, we can leverage some of that safety data going forward and maybe generate a little bit more of a lean strategy in Factor VII deficiency.

Maury Raycroft, Analyst — Jefferies

Okay. Interesting. And how many Glanzman and Factor VII deficiency patients do you think are undiagnosed are undiagnosed or undertreated because of lack of prophy options, and is there a large latent patient population that could emerge?

Benny Sorensen, CEO

Mario, I feel like we've had this discussion a couple of times. We know there is 10,000 patients in U.S., Europe, Gulf states, Japan, and a small part of the rest of the world, which combined with Glantzman's, in fact, seven deficiency. The question is, is there a hidden population? I don't think it's like, you know, for instance, you know, PNH, where, you know, in the early In the early days of Alexion's journey to Omega first-ever prophy, it was probably one in a million, and now it's like, you know, on national TV, it's, you know, easily 10 times higher prevalence. I don't think that's the case for Glansman, in fact, 7 deficiency. I think that there will always be a pocket of, you know, a percentage of patients that are not known or has been lost in the system because there wasn't modern therapies. I will say, though, there is a potentially interesting added opportunity in Factor 7 deficiency. The 5,000 patients with Factor 7 is assuming we are only targeting the most severe. Now, if the drug is safe and efficacious, I can easily imagine that you would start, you know, treating patients with moderate, and that could boost the numbers very significantly.

Maury Raycroft, Analyst — Jefferies

Got it. What does that look like again?

Benny Sorensen, CEO

So, you know, the rare is like, you know, 1 in 500,000. You know, the moderate is like 1 in 20,000. So it's much more prevalent.

Maury Raycroft, Analyst — Jefferies

And for cetazamig, are there other opportunities beyond?

Benny Sorensen, CEO

You know what, you can somewhat say the clinical validation by Novo7 has generated almost like a GPS roadmap for Cytasomec. Now it's Glansman, it's Factor 7 deficiency. We can go to Bernard Soulier, we can go to other platelet disorders. Of course, this is, you know, a treatment that also will have effect in the very treatment-resistant, you know, hemophilia A and B. So, you know, it's... I know this sounds like a cliche, right, but it has the opportunity of being a bit of a pipeline within one drug.

Maury Raycroft, Analyst — Jefferies

Right, yeah, yeah, interesting. Your second asset is HMB02 for von Willebrand disease. You've shown some early safety data, but a more robust update is expected at EHOD in February. Where are you at with dosing in the sad and mad phases at this point?

Benny Sorensen, CEO

Yeah, so we've shown data from three cohorts at ISGH in July, 20 milligrams, 50 milligrams, and 150 milligrams, total of 13 patients. The drug is doing what it was designed to do. We see nice dose proportionality. The higher the dose, the longer the duration of effect. And we see really compelling increases in the relevant factor and factor VIII, give or take 2.5-fold increase. Just, you know, it's a fun fact. When we kind of started this journey, we were convinced if we get 1.5-fold, we have a really successful drug. Now, we have 2.5-fold, and actually, on average, we are normalizing levels of enrollment factor and factor 8 in the population we have studied. That, you know, I'm thinking about that as a, you know, as a clinician. This is a super compelling profile. That you can, you know, measure levels, give a drug, you can measure the effect, and if they're in the normal range, your advice to these patients is go home, live your life. That is just so exciting. So that's where we are. That's 13 patients come year ahead in February. We will add an additional 300 milligram dose cohort in the single ascending dose, and we will show the first data emerging out of the 150 milligram monthly multiple dose.

Maury Raycroft, Analyst — Jefferies

Got it. Okay.

Benny Sorensen, CEO

And total number of patients, Maurice, like it's 8 to 10 additional patients. So now we have, you know, nicely over 20 patients' worth of data to start generating, you know, I think a total look into data. People are often asking, what is your number one variable, you know, that you're excited about? I think if we can continue to see, you know, a red line between PK, translating to PD, translating to coagulation activity, and actual clinical observations, we will be super excited.

Maury Raycroft, Analyst — Jefferies

Yeah, yeah, it makes sense. And for this program, you've got approximately 110 patients in your prospective natural history run-in Valora study. What magnitude of ABR reduction in your ongoing study versus the run-in in Valora would you view as sufficient to move O2 into registration study?

Benny Sorensen, CEO

Yeah. So, by the way, I think the Valora Discover, we've not talked a lot about it. I'm not sure we're going to talk a lot about it because it actually generates a goldmine of highly proprietary data, understanding what is the characteristics of, you know, the clinical phenotype of Verlopen's disease, in particular type 1, type 2A, constituting the vast majority of the patients. Getting an insight into, you know, what fraction of those patients are actually bleeding very frequently, what's their characteristics, you know, what's the variability in bleeds, all of those things that can actually enable us to do a really powerful, successful pivotal trial. Therefore, we're not going to talk a lot about it because that would be giving away, you know, important information. I think your question was, what reduction? Remember, we are looking at prospectively collected, annualized, treated bleeds. So they have real clinical significance. There are accountability built in, because the second you treat, you can go back and verify that the treatment has been given. And in our kind of correspondence with payers, it's pretty clear that treated bleeds are reimbursable bleeds. Not treated bleeds is don't pay for that. So we are collecting that data. In von Robben's disease, as a minimum, you want to see at least 50% reduction. More is better. But I think at this early stage, that's the right guidance. We want to have a very clear signal, in effect. And I know that every single good analyst, including yourself, would be like, ah, you know, what exact number do you want to get to? It's going to be, you know, preliminary still. I wouldn't really put my head on the block on a certain number.

Maury Raycroft, Analyst — Jefferies

But comparing to Valora, basically you're saying that's not going to be possible because you're not going to share any data from that study.

Benny Sorensen, CEO

Well, you know, the patients that enroll into the Phase 2, of course we will show that data. You know, we don't show population-based data because that is, you know, really a trade secret for the company.

Maury Raycroft, Analyst — Jefferies

Yeah, makes sense. And so you're saying you want to see all the measures aligned, so PK, PD, and then see the blood, the bleeding reductions. Potentially the 50% bar is what you've mentioned. I guess how do you contextualize this versus the Insight Star data where they showed approximately 80%, but it was in a small number of patients?

Benny Sorensen, CEO

And by the way, it's a totally fair question. You know, how do you compare? Unfortunately, the way we are, each of us have made strategic decisions conducting these trials makes that comparison pretty much impossible. InSight is collecting baseline beta based on patient's individual retrospective recall, and they're asking them to estimate total number of bleeds, irrespective of whether they were treated or not. Our approach is patients are being enrolled in a prospective trial, fully GCP monitored. We are prospectively collecting that for a minimum of four months. So those two variables are just not comparable at all. And therefore, you know, you can show 80% here, and you cannot compare that to, you know, a reduction in our data set. I think one of the real strengths that we have is this is a treatment that you can monitor. So, if a patient comes in, he has 20% enrollment factor and 35% factor 8, you can give HMBO2, and then, you know, a week later, you could invite the patient in, and you can monitor it. You've got effect. Right. I think that is really compelling.

Maury Raycroft, Analyst — Jefferies

Yeah, yeah. And basically, you'll be able to know if you're having an effect in these patients, and so you'll determine that information. For seeing longer-term follow-up for these patients, I guess, when does that become more meaningful over time?

Benny Sorensen, CEO

Yes, I think, you know, all of them will have minimum four months baseline, and we will have up to four months of follow-up on treatment in the multiple dose. And then you can ask, you know, when is the number, you know, sufficient to kind of generate a good quantitative estimate? I don't think the first cohort is like that. But, hey, there's good interest in the trial. I'm convinced that, you know, in 27, we'll get to an understanding on all what is needed for us to transition to the next stage. And I think everybody should expect that from phase 1-2, it is transitioned straight to a single epimetric trial.

Maury Raycroft, Analyst — Jefferies

Okay. Okay. That's helpful. And while we're still on the topic, with the Insight drug, VGA039, maybe just talk about how your drug compares with that, and what do you expect them to show in their longer-term data at ASH?

Benny Sorensen, CEO

Yeah. So, you know, we are, by the way, we see a little bit ourselves as collaborators with Insight Because we're both generating a lot of awareness and interest in vulnerable disease, and we are kind of coming at it at really distinctly different angles. HMbO2 is designed as a monovalent antibody. It targets endogenous residual vulnerable factor. It generates a high affinity binding, so it's almost like an in vivo half-life extension of vulnerable factor. And that then leads to an increase in vulnerable factor and increase in factor 8. So from a mechanism of action point of view, it is really intuitive and simple. We directly target. We directly correct the underlying pathophysiology. And our friends at Insight is kind of pursuing this from a more, you know, experimental therapeutic hypothesis point of view, investigating if inhibition of a natural anticoagulant like protein S can bypass from relevant factor and bypass factor VIII. I actually... First and foremost, believe in innovation. It's good for patients. It's good for competition. And I'm sure there will be patient pockets that will benefit from that, you know, treatment strategy. I'm super biased, Maury. I believe many more patients will benefit from HMBO, too.

Maury Raycroft, Analyst — Jefferies

Right. Yeah. And that makes sense. And you mentioned potentially moving from the Phase 1-2 directly into a Phase 3 study. When do you expect the end of Phase 2 FDA interaction to take place, and how quickly?

Benny Sorensen, CEO

Yeah, you know, let's see the next batch of data, and I think we can provide a little bit more, you know, data-driven guidance on when we think we can be in a position to transition. Meanwhile, right, Valora Discover remains open, and we will build a repository of patients with, you know, baseline data. There's no doubt that you need to really understand with high-quality data what's the baseline bleed rate. You've got to have eligibility criteria so there are significant enough bleeds to actually see a treatment effect.

Maury Raycroft, Analyst — Jefferies

Yeah, and going back to the broad treatment and what you think you could treat with OO2, with this disease there's a lot of heterogeneity. Which subtypes do you think would respond best to OO2 versus BGA-039?

Benny Sorensen, CEO

Yeah, O2, you know, the data we have already, a high degree of confidence in all type 1. At EAHAD in February, we will show data both in type 1 and type 2A. And if you think about it, you know, 80% of patients have type 1. Another 10-15% of patients have type 2A, so, you know, if we can convince ourselves we have effect in those two, we are looking at about 90-95% of all patients with rheumatoid disease. The remaining 5%, it's a little bit of a mixed bag, type 2B, 2M, 2N, and, of course, a very small pocket of type 3. As part of our phase 1-2, we will look into co-administering HMBO2 with a rheumatoid factor concentrate. Not that 250 or 300 patients in the United States can kind of move the business case, but we know the physicians would do this. I think it's a cool experiment to do. So we will generate that data. But for now, the focus is really on type 1, type 2A. It constitutes the vast majority of patients.

Maury Raycroft, Analyst — Jefferies

When would you be able to generate the data with the von Willemburg factor?

Benny Sorensen, CEO

We'll let you know.

Maury Raycroft, Analyst — Jefferies

Yeah, okay. Let's see. Let's shift gears. We'll talk about your third program, HMB03, centered the clinic, healthy volunteers, key competitors, L-nylam, targeting upstream with their siRNA. Can you compare and contrast your approach versus L-nylam's and where you can see differentiation show up on safety in particular?

Benny Sorensen, CEO

Disclaimer, right? Previous L-nylam employee. I may say something nice about them. Hey, you know, first and foremost, let's think about the way we have engineered HMbO3 plasmin as a target. It's a clinically validated target in heavy menstrual bleeding. It's also a genetically validated target in heavy menstrual bleeding. So a high degree of conviction that that's the right target if you want to control heavy menstrual bleeding. From a modality point of view, we've used a fatty acid conjugated peptide, you know, same technology framework as GLP-1's. And it really has pharmacokinetic properties that are ideal for heavy menstrual bleeding. One sub-q shot, within very few hours, you have C-max, so you very promptly get max pharmacological effect. It's engineered with fatty acid compositions to kind of then, you know, have the most pharmacological effects, you know, during the early days of the menstrual bleed and then fade out again. The fade-out is super important because what we know from congenital plasminogen deficiency is constant inhibition of plasmin can lead to really serious extravascular fibrin depositions. They can be easy to see. You know, you can see them in the eye and the mouth. But for women, those extravascular fibrin depositions can occur in the cervix and the fallopian tubes. And just at ISGH in July, population-based data in plasminogen deficiency showed that 40% of women with plasminogen deficiency become infertile. For us, recovering plasmin so that you can clear all of those extravascular tubes is absolutely essential. You know, the siRNA technology, right, it's potent, it's durable, extremely durable, and it will lead to kind of an acquired plasminogen deficiency-like state. I think the benefit-risk in HHT makes good sense, maybe a little harder to kind of understand benefit-risk in heavy menstrual bleeding, in particular, if there's a risk of infertility. The challenge with infertility is you can't see. So you can't monitor if your fallopian tubes are getting clocked up.

Maury Raycroft, Analyst — Jefferies

Yeah, interesting. And you're going to have some NHP data at ASH. Maybe talk briefly about the findings there and how translatable you think the data is.

Benny Sorensen, CEO

By the way, I think one of the coolest preclinical experiments we've done, we've followed a group of female non-human primates, identified those that have regular menstrual bleeds, It's further selected for those who have a severe bleeding rating, generate a baseline, and then put them on HMBO3. In the abstract, we are saying we can see a very, you know, distinct reduction in the severe bleed days, and we'll show the actual quantitative data there. Is that translatable? You know, it's the closest we can get to a preclinical model of kind of a registrational trial in heavy menstrual bleeding. So super excited about that. I think it's a good initial look into what to kind of expect.

Maury Raycroft, Analyst — Jefferies

How much follow-up do you have on the NHPs?

Benny Sorensen, CEO

So, it's a very, very long study, so there's a minimum of two periods before, two periods after treatment.

Maury Raycroft, Analyst — Jefferies

Got it. Interesting. And then for your initial healthy volunteer data in mid-27, what are you going to show there, and how quickly can you get this program into later stages?

Benny Sorensen, CEO

Yeah, so right now it's a randomized placebo-controlled trial in health volunteers. It's safety PK. PK is important because part of the targeted profile is to confirm that we have pharmacokinetics that, you know, supports that one-stop cue shot. The PD is actually very, you know, informative as, you know, other studies done with plasmid inhibition like tranexamic acid. We can see what was effective in those trials. And we can use the PD to kind of say, okay, this is the dose that is going to give the most favorable effect. So usually phase one studies is a little boring, but in this particular case, I actually think the totality, both PK and PD, can be quite exciting.

Maury Raycroft, Analyst — Jefferies

Got it. I didn't realize we had a minus sign in front of our timer here.

Benny Sorensen, CEO

I don't like minus, you know.

Maury Raycroft, Analyst — Jefferies

But since we're over on time, maybe just to close out, if you could talk about pro forma cash and runway assumptions and then key catalysts ahead.

Benny Sorensen, CEO

Yeah, there is nicely more than $400 million in the bank, runway well into 2029. There's a lot of data coming up. In ASH, we have FAC7 deficiency data. In February, we have enrollment disease data. And in mid-27, we have the first data on HMB03. We can populate the remainder of the calendar year with more data later.

Maury Raycroft, Analyst — Jefferies

Okay. Well, great. Thanks so much for joining us. Awesome.

Benny Sorensen, CEO

Thank you, Mark.